In its software, Lykos describes MDMA being a catalyst with the therapeutic approach, Which is the reason it obtained a great deal awareness. That's not predicted to generally be as much of the hold-up for other psychedelics, though. “The rest of us are finding out molecules that do not demand the same degree of therapy,” states Kabir Nath, CEO